Business Context and Reporting Period
Company: Teleflex Incorporated (Teleflex)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Teleflex is a global provider of medical technology products, aerospace cargo systems, and commercial marine/rigging products. The company operates through three segments: Medical (77% of 2009 revenue), Aerospace (10%), and Commercial (13%). The Medical segment focuses on critical care, surgical care, and cardiac care devices. The company has been actively restructuring its portfolio, divesting non-core aerospace and commercial businesses while expanding its medical footprint, notably through the 2007 acquisition of Arrow International.
Key Financial Metrics
| Metric | 2009 | 2008 | 2007 |
|---|---|---|---|
| Net Revenues | $1,890.1 million | $2,066.7 million | $1,575.1 million |
| Gross Profit | $814.1 million | $855.0 million | $591.8 million |
| Gross Margin | 43.1% | 41.4% | 37.6% |
| Income from Continuing Operations | $142.9 million | $98.1 million | ($31.7 million) |
| Net Income (Total) | $314.0 million | $154.6 million | $177.2 million |
| Diluted EPS (Continuing Ops) | $3.55 | $2.44 | ($0.82) |
| Free Cash Flow | $159.4 million | $70.5 million | $192.9 million |
| Total Debt (Outstanding) | $1.2 billion | $1.5 billion | $1.5 billion |
| Cash and Cash Equivalents | $188.3 million | $107.3 million | $201.3 million |
Material Changes vs. Prior Period
- Revenue Decline: Net revenues decreased 9% to $1.89 billion in 2009 compared to 2008. This was driven by a 6% decline in core business (primarily Aerospace and Commercial segments) and a 3% negative impact from foreign currency fluctuations (stronger U.S. dollar).
- Segment Performance:
- Medical: Revenues declined 3% due entirely to currency impacts; core revenue was flat. Operating profit increased 7% to $305.1 million due to cost reductions and the absence of a $7 million inventory fair value adjustment that occurred in 2008.
- Aerospace: Revenues dropped 27% and operating profit fell 41% due to weak commercial aviation demand and reduced aircraft utilization.
- Commercial: Revenues declined 21% and operating profit fell 42% due to softness in the recreational marine market and rigging services.
- Profitability: Despite lower revenues, the effective tax rate dropped significantly to 21.8% in 2009 from 32.6% in 2008, aided by lower state tax liabilities and reduced reserves for uncertain tax positions.
- Debt Reduction: Total indebtedness decreased by approximately $300 million to $1.2 billion, primarily funded by proceeds from the sale of the ATI Singapore business ($300 million) and Power Systems operations.
- Discontinued Operations: Significant income was generated from discontinued operations ($171.1 million in 2009), largely due to the sale of the ATI Singapore joint venture and Power Systems, which included a $272.3 million gain on disposal.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects modest improvement in the U.S. and global economy but notes that recessionary conditions could continue to impact Aerospace and Commercial segments. The Medical segment is expected to face pressure from hospital budget constraints and potential healthcare reform legislation.
- Restructuring: The company is executing integration plans for the Arrow acquisition and restructuring programs in the Commercial segment. Future restructuring charges for the Arrow integration are estimated at $1.3 million to $2.3 million in 2010.
- Unusual Items:
- Impairment Charges: Recorded $6.7 million in goodwill impairment (Cargo Container reporting unit) and $2.3 million in intangible asset impairment (Marine reporting unit) in 2009.
- Product Recall: In Q1 2010 (subsequent to year-end), a voluntary recall of custom IV tubing was initiated with estimated costs of $4.5 million to $7.5 million. $1.7 million was accrued in 2009.
- Risks:
- Regulatory: Ongoing resolution of FDA corporate warning letter issues regarding Arrow International quality systems. Potential impact of U.S. healthcare reform on reimbursement rates and potential medical device taxes.
- Economic: Exposure to global economic downturns affecting aerospace and commercial marine markets. Currency exchange rate fluctuations impacting international revenues.
- Debt Covenants: The company maintains a consolidated leverage ratio of 2.95:1 and an interest coverage ratio of 4.92:1, both in compliance with debt covenants (limits are 3.50:1).
Key Facts for Investor Verification
- Debt Servicing: Verify the company's ability to service $1.2 billion in debt, with significant principal payments due in 2011 ($145 million) and 2012 ($769 million), relying on foreign cash repatriation and operating cash flow.
- FDA Compliance: Monitor the status of the FDA corporate warning letter issued to Arrow International in 2007 and the outcome of re-inspections completed in late 2009.
- Healthcare Reform Impact: Assess the potential financial impact of pending U.S. healthcare legislation on Medicare/Medicaid reimbursement rates and the proposed medical device manufacturer tax.
- Discontinued Operations: Distinguish between continuing operations performance and the one-time gains from the sale of ATI Singapore and Power Systems, which significantly boosted 2009 net income.
- Accounting Change: Note the upcoming adoption of new accounting standards in Q1 2010 regarding accounts receivable securitization, which will reclassify $39.7 million from operating cash flow to financing cash flow and increase reported short-term debt.